<DOC>
	<DOCNO>NCT01537172</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ONO-4053 across ascend single multiple dos healthy adult male female subject . The secondary objective study characterize pharmacokinetic profile ONO-4053 healthy adult male female subject .</brief_summary>
	<brief_title>A Phase I Study Evaluate Safety , Tolerability Pharmacokinetics ONO-4053 Healthy Volunteers</brief_title>
	<detailed_description>Ono Pharma UK Ltd European subsidiary Ono Pharmaceutical Co. Ltd. As European Legal Representative Ono Pharmaceutical Co. Ltd , Ono Pharma UK Ltd carry study . This clinical study ONO-4053 healthy volunteer . This study consist three part . Part A investigate safety , tolerability pharmacokinetics single ascend dos ONO-4053 administer double-blind manner . Part B investigate pharmacokinetics ONO-4053 fed fast state open-label manner . Part C investigate safety , tolerability pharmacokinetics multiple ascend dos ONO-4053 administer double-blind manner . Doses Part B C determine data Part A available .</detailed_description>
	<criteria>Healthy caucasian subject age 1845 year inclusive . Subjects body mass index 1930 kg/m2 inclusive weigh least 50 kg 100 kg screening . Subjects clinically relevant history presence clinically significant disease disorder . Current smoker smoke used nicotine product within 6 month Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ONO-4053 healthy subject</keyword>
	<keyword>3 part adaptive design</keyword>
</DOC>